Peapod Lane Capital LLC lessened its holdings in shares of Ikena Oncology, Inc. (NASDAQ:IKNA - Free Report) by 41.6% in the first quarter, according to its most recent filing with the SEC. The firm owned 296,437 shares of the company's stock after selling 211,431 shares during the quarter. Peapod Lane Capital LLC owned about 0.61% of Ikena Oncology worth $379,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently modified their holdings of IKNA. Gilead Sciences Inc. bought a new stake in shares of Ikena Oncology during the fourth quarter valued at about $3,294,000. Geode Capital Management LLC increased its stake in Ikena Oncology by 21.0% during the 4th quarter. Geode Capital Management LLC now owns 327,962 shares of the company's stock valued at $538,000 after buying an additional 56,936 shares during the period. JPMorgan Chase & Co. raised its position in shares of Ikena Oncology by 18,244.1% during the 4th quarter. JPMorgan Chase & Co. now owns 155,741 shares of the company's stock worth $255,000 after buying an additional 154,892 shares in the last quarter. Northern Trust Corp lifted its stake in shares of Ikena Oncology by 19.7% in the 4th quarter. Northern Trust Corp now owns 57,565 shares of the company's stock worth $94,000 after acquiring an additional 9,456 shares during the period. Finally, BNP Paribas Financial Markets bought a new position in shares of Ikena Oncology in the fourth quarter valued at approximately $72,000. Institutional investors own 75.00% of the company's stock.
Ikena Oncology Price Performance
Shares of NASDAQ IKNA traded down $0.01 during mid-day trading on Friday, reaching $1.38. 40,273 shares of the company traded hands, compared to its average volume of 114,651. Ikena Oncology, Inc. has a fifty-two week low of $0.97 and a fifty-two week high of $1.94. The firm has a market cap of $66.60 million, a PE ratio of -1.60 and a beta of 0.50. The stock has a fifty day simple moving average of $1.27 and a 200-day simple moving average of $1.34.
Ikena Oncology (NASDAQ:IKNA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.03. As a group, analysts predict that Ikena Oncology, Inc. will post -0.91 EPS for the current fiscal year.
Ikena Oncology Profile
(
Free Report)
Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.
Featured Stories
Before you consider Ikena Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ikena Oncology wasn't on the list.
While Ikena Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
